FT206
Based on 1 publication(s) in Google Scholar
FT206 is the inhibitor for ubiquitin-specific protease that inhibits USP28 and USP25 with IC50s of 0.15 μM and 1.01 μM.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.40%
- CAS No.: 2278274-34-1
- Formule: C25H29N5OS
- Masse moléculaire:447.60
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Ubiquitination Compound Library
HY-L050
-
Orally Active Compound Library
HY-L061
-
Heterocyclic Compound Library
HY-L138
-
Metabolic Enzyme Compound Library
HY-L146
-
Protease Inhibitor Library
HY-L147
-
Highly Selective Inhibitors Library
HY-L158
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
Publications Citing Use of MedChemExpress (MCE) FT206
More
Activité biologique
IC50: USP28 (0.15 μM); USP25 (1.01 μM)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Calu-1 | IC50 |
0.32 μM
Compound: FT206
|
Antiproliferative activity against human Calu-1 cells assessed as cell growth inhibition incubated for 3 days by SRB assay
Antiproliferative activity against human Calu-1 cells assessed as cell growth inhibition incubated for 3 days by SRB assay
|
[PMID: 37075624] |
| HCT-116 | IC50 |
0.19 μM
Compound: FT206
|
Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition incubated for 3 days by SRB assay
Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition incubated for 3 days by SRB assay
|
[PMID: 37075624] |
| LS174T | IC50 |
0.07 μM
Compound: FT206
|
Antiproliferative activity against human LS174T cells assessed as cell growth inhibition incubated for 3 days by SRB assay
Antiproliferative activity against human LS174T cells assessed as cell growth inhibition incubated for 3 days by SRB assay
|
[PMID: 37075624] |
| NCI-H226 | IC50 |
0.15 μM
Compound: FT206
|
Antiproliferative activity against human NCI-H226 cells assessed as cell growth inhibition incubated for 3 days by SRB assay
Antiproliferative activity against human NCI-H226 cells assessed as cell growth inhibition incubated for 3 days by SRB assay
|
[PMID: 37075624] |
FT206 (0-5 μM, 48-96 h) suppresses the expression of c-JUN and c-MYC in primary lung squamous cell carcinoma (LSCC), and inhibits the proliferation of KF LSCC cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:primary lung squamous cell carcinoma
-
Concentration:0-100 nM
-
Incubation Time:48 h
-
Result:Inhibited the expression of c-JUN and c-MYC.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:H520 xenograft KRasLSL-G12D; Fbxw7flox/flo mouse model[3]
-
Dosage:75 mg/kg
-
Administration:po, three times a week for 5 weeks
-
Result:Inhibited the tumor growth.
Chemical Information
-
CAS No. 2278274-34-1
-
Appearance Solid
-
Masse moléculaire 447.60
-
Formule C25H29N5OS
-
Color Light yellow to yellow
-
SMILES
O=C(C1=C(C2=CC=C(C)N=C2S1)N)N[C@@H]3CC4=CC=C(N5CC6NC(CC6)C5)C=C4CC3
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Cell Chem Biol
2025 Sep 1:S2451-9456(25)00232-6. PMID: 40902594
Solvant et solubilité
DMSO : 150 mg/mL (335.12 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL (11.17 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 3.75 mg/mL (8.38 mM); Clear solution
This protocol yields a clear solution of ≥ 3.75 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (37.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (275 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. WO2020033707
[2]. Diep YN, et al., Astrocytic scar restricting glioblastoma via glutamate-MAO-B activity in glioblastoma-microglia assembloid. Biomater Res. 2023 Jul 19;27(1):71. [Content Brief]
[3]. Ruiz EJ, et al., USP28 deletion and small-molecule inhibition destabilizes c-MYC and elicits regression of squamous cell lung carcinoma. Elife. 2021 Oct 12;10:e71596. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2341 mL | 11.1707 mL | 22.3414 mL | 55.8534 mL |
| 5 mM | 0.4468 mL | 2.2341 mL | 4.4683 mL | 11.1707 mL | |
| 10 mM | 0.2234 mL | 1.1171 mL | 2.2341 mL | 5.5853 mL | |
| 15 mM | 0.1489 mL | 0.7447 mL | 1.4894 mL | 3.7236 mL | |
| 20 mM | 0.1117 mL | 0.5585 mL | 1.1171 mL | 2.7927 mL | |
| 25 mM | 0.0894 mL | 0.4468 mL | 0.8937 mL | 2.2341 mL | |
| 30 mM | 0.0745 mL | 0.3724 mL | 0.7447 mL | 1.8618 mL | |
| 40 mM | 0.0559 mL | 0.2793 mL | 0.5585 mL | 1.3963 mL | |
| 50 mM | 0.0447 mL | 0.2234 mL | 0.4468 mL | 1.1171 mL | |
| 60 mM | 0.0372 mL | 0.1862 mL | 0.3724 mL | 0.9309 mL | |
| 80 mM | 0.0279 mL | 0.1396 mL | 0.2793 mL | 0.6982 mL | |
| 100 mM | 0.0223 mL | 0.1117 mL | 0.2234 mL | 0.5585 mL |
FT206 Related Classifications
HY-138698 Related Classifications
Powered by Bioz